Tenax Therapeutics Reports Q4 Loss

Biopharmaceutical company posts $15.5 million deficit in latest quarter

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Tenax Therapeutics Inc., a biopharmaceutical company based in Chapel Hill, North Carolina, reported a loss of $15.5 million in its fourth quarter, according to an announcement from the company.

Why it matters

Tenax Therapeutics is a publicly traded company focused on developing treatments for cardiovascular and pulmonary diseases. The company's quarterly financial results are closely watched by investors and analysts to gauge its financial health and progress in advancing its drug pipeline.

The details

The $15.5 million loss reported by Tenax Therapeutics for the fourth quarter reflects the company's ongoing research and development expenses as it works to bring new therapies to market. As a biopharmaceutical firm without any approved products yet, Tenax relies on investor funding to sustain its operations.

  • Tenax Therapeutics reported its Q4 2025 financial results on March 10, 2026.

The players

Tenax Therapeutics Inc.

A biopharmaceutical company based in Chapel Hill, North Carolina that is focused on developing treatments for cardiovascular and pulmonary diseases.

Got photos? Submit your photos here. ›

The takeaway

Tenax Therapeutics' Q4 loss highlights the financial challenges facing early-stage biopharmaceutical companies as they work to advance their drug pipelines without any approved products generating revenue. Investors will be closely monitoring the company's progress in the months ahead as it seeks to reach key milestones in its clinical trials.